Oruka Therapeutics Q1 FY26 net loss widens 52% to $31.82 million

• Oruka Therapeutics posted a wider net loss of USD 31.82 million, up 52% from year-ago quarter.
• Operating loss widened to USD 36.43 million, a 45% deterioration, as total operating expenses climbed 45% to USD 36.43 million.
• Research and development costs rose 46% to USD 29.15 million, while general and administrative spending increased 41% to USD 7.29 million.
• Cash, cash equivalents, and marketable securities totaled USD 496 million as of March 31, 2026; April underwritten offering raised gross proceeds of USD 700.4 million.
• Phase 2a EVERLAST-A Week 16 data showed 63.5% of ORKA-001 patients achieved PASI 100; Phase 2 ORCA-SURGE trial of ORKA-002 in psoriasis began in February 2026 with data expected in 2027.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Oruka Therapeutics Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001213900-26-055769), on May 13, 2026, and is solely responsible for the information contained therein.